Arcutis (ARQT) insider trade: 17,250 options exercised and shares sold

Q: What did ARQT’s officer report on the Form 4 dated 11/06/2025?

An option exercise for 17,250 shares at $3.64 and a sale of 17,250 shares at a weighted average price of $24.1823 .

Q: What price range were ARQT shares sold at on 11/06/2025?

Multiple trades occurred between $23.79 and $24.4493 , with a weighted average of $24.1823 .

Q: How many ARQT shares does the reporting person hold after the transactions?

Beneficial ownership is 98,325 common shares and 155,250 derivative securities (options).

Q: What are the vesting terms of the ARQT stock options referenced?

Options granted on January 12, 2024 vest 1/48th monthly , fully vesting on the fourth anniversary, subject to continued service.

Q: What is the reporting person’s role at Arcutis Biotherapeutics (ARQT)?

The filing lists the role as Executive Vice President and Chief Medical Officer .

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics (ARQT) insider transaction: On 11/06/2025, the company’s Executive Vice President and Chief Medical Officer exercised stock options for 17,250 shares at $3.64 and sold 17,250 common shares at a weighted average price of $24.1823, with trades executed between $23.79 and $24.4493. The transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.

Following these transactions, the reporting person beneficially owned 98,325 shares of common stock and 155,250 derivative securities (options). The reported option grant vests monthly over four years from January 12, 2024, until fully vested on the fourth anniversary.

Insights

Routine Form 4: option exercise and same‑day sale under 10b5‑1 plan.

The officer exercised stock options for 17,250 shares at $3.64 on 11/06/2025 and sold the same number of shares at a weighted average of $24.1823 (range $23.79–$24.4493). The filing states these trades were executed pursuant to a Rule 10b5‑1 plan adopted on December 12, 2024.

Post‑trade holdings are disclosed as 98,325 common shares and 155,250 derivative securities. The option grant vests monthly beginning January 12, 2024 and fully vests by January 12, 2028, subject to continued service. Actual market impact depends on trading volume and was not detailed here.

Insider Trade Summary

Net Seller: 17,250 shares ($417,145)

Net Sell 3 txns

Insider Burnett Patrick

Role See Remarks

Sold 17,250 shs ($417K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	17,250	$0.00	--
Exercise	Common Stock	17,250	$3.64	$63K
Sale	Common Stock	17,250	$24.1823	$417K

Holdings After Transaction: Stock Option (right to buy) — 155,250 shares (Direct); Common Stock — 115,575 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.79 to $24.4493, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Form 4 Insider Transactions: What Each Field Means →

11/10/2025 - 05:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

91361

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/06/2025		M⁽¹⁾		17,250⁽¹⁾	A	$3.64	115,575	D
Common Stock	11/06/2025		S⁽¹⁾		17,250	D	$24.1823⁽²⁾	98,325	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.64	11/06/2025		M⁽¹⁾			17,250	⁽³⁾	01/12/2034	Common Stock	17,250	$0	155,250	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.79 to $24.4493, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Reporting Person's Title: Executive Vice President and Chief Medical Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ARQT’s officer report on the Form 4 dated 11/06/2025?

An option exercise for 17,250 shares at $3.64 and a sale of 17,250 shares at a weighted average price of $24.1823.

Was the ARQT insider sale made under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5‑1 plan adopted on December 12, 2024, ending February 27, 2026.

What price range were ARQT shares sold at on 11/06/2025?

Multiple trades occurred between $23.79 and $24.4493, with a weighted average of $24.1823.

How many ARQT shares does the reporting person hold after the transactions?

Beneficial ownership is 98,325 common shares and 155,250 derivative securities (options).

What are the vesting terms of the ARQT stock options referenced?

Options granted on January 12, 2024 vest 1/48th monthly, fully vesting on the fourth anniversary, subject to continued service.

What is the reporting person’s role at Arcutis Biotherapeutics (ARQT)?

The filing lists the role as Executive Vice President and Chief Medical Officer.